Journal of Neuropathology & Experimental Neurology · 2007 · 44 citations · 30 references
Cell DeathNeurochemical BiomarkersSocial SciencesAutophagyNeurologyNeuropathologyMolecular NeuroscienceMotor NeuronsNeurodegenerationGene ExpressionCell BiologyAmyotrophic Lateral SclerosisDynactin 1NeurophysiologyResidual Motor NeuronsNeuroscienceMolecular NeurobiologyCentral Nervous SystemMedicineDeath Receptor 5
In a differential gene expression profile, we showed previously that dynactin 1 (DCTN1), early growth response 3 (EGR3), acetyl-CoA transporter (ACATN), death receptor 5 (DR5), and cyclin C (CCNC) were prominently up- or downregulated in motor neurons of sporadic amyotrophic lateral sclerosis (ALS). In the present study, we examined the correlation between the expression levels of these genes and the levels of pathologic markers for motor neuron degeneration (i.e. cytoplasmic accumulation of phosphorylated neurofilament H [pNF-H] and ubiquitylated protein) and the numbers of residual motor neurons in 20 autopsies of patients with sporadic ALS. DCTN1 and EGR3 were widely downregulated, and the changes in gene expression were correlated to the number of residual motor neurons. In particular, DCTN1 was markedly downregulated in most residual motor neurons before the accumulation of pNF-H, even in cases with well-preserved motor neuron populations. ACATN, DR5, and CCNC were upregulated in subpopulations of residual motor neurons, and their expression levels were well correlated with the levels of pNF-H accumulation and the number of residual motor neurons. The expressions of DCTN1, EGR3, ACATN, and DR5 were all markedly altered before ubiquitylated protein accumulation. DCTN1 downregulation appears to be an early event before the appearance of neurodegeneration markers, whereas upregulations of DR5 and CCNC are relatively later phenomena associated with pathologic markers and leading to neuronal death. The sequence of motor neuron-specific gene expression changes in sporadic ALS can be beneficial information in developing appropriate therapeutic strategies for neurodegeneration.
30
Mutant dynactin in motor neuron disease
Imke Puls, Catherine Jonnakuty, Bernadette H. LaMonte et al. · Nature Genetics · 2003 · 944 citations · Full text
Neurodegenerative Diseases, Molecular Neuroscience, Medicine +9
RNA editing and death of motor neurons
Yukio Kawahara, Kyoko Ito, Hui Sun et al. · Nature · 2004 · 541 citations · Full text
Neurodegenerative Diseases, Molecular Neuroscience, Motor Neurons +6